The Influence of Oxytocin and Prolactin During a First Episode of Psychosis: The Implication of Sex Differences, Clinical Features, and Cognitive Performance.
First-episode psychosis
cognition
oxytocin
prolactin
sexual dimorphism
Journal
The international journal of neuropsychopharmacology
ISSN: 1469-5111
Titre abrégé: Int J Neuropsychopharmacol
Pays: England
ID NLM: 9815893
Informations de publication
Date de publication:
16 08 2022
16 08 2022
Historique:
received:
17
12
2021
revised:
10
03
2022
accepted:
24
03
2022
pubmed:
31
3
2022
medline:
19
8
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
Approximately 3% of the population suffers a first episode of psychosis (FEP), and a high percentage of these patients subsequently relapse. Because the clinical course following a FEP is hard to predict, it is of interest to identify cognitive and biological markers that will help improve the diagnosis, treatment, and outcome of such events and to define new therapeutic targets. Here we analyzed the plasma oxytocin and prolactin levels during an FEP, assessing their correlation with clinical and cognitive features. The oxytocin and prolactin in plasma was measured in 120 FEP patients and 106 healthy controls, all of whom were subjected to a clinical and neuropsychological assessment. Most patients were under antipsychotics. Statistical analyses aimed to identify factors associated with the FEP and to search for associations between the variables. This study is preliminary and exploratory because the P-values were not corrected for multiple comparisons. FEP patients had less oxytocin, more prolactin, and a poor premorbid IQ, and they performed worse in sustained attention. Male patients with higher prolactin levels experienced more severe psychotic symptoms and required higher doses of antipsychotics. Low oxytocin was associated with poor sustained attention in women, whereas low oxytocin and high prolactin in men correlated with better performance in sustained attention. Low oxytocin, high prolactin, and poor premorbid IQ and sustained attention are factors associated with an FEP, representing potential therapeutic targets in these patients. These biological factors and cognitive domains might play an important role during a FEP, which could help us to develop new strategies that improve the outcomes of this disorder and that should perhaps be gender specific.
Sections du résumé
BACKGROUND
Approximately 3% of the population suffers a first episode of psychosis (FEP), and a high percentage of these patients subsequently relapse. Because the clinical course following a FEP is hard to predict, it is of interest to identify cognitive and biological markers that will help improve the diagnosis, treatment, and outcome of such events and to define new therapeutic targets. Here we analyzed the plasma oxytocin and prolactin levels during an FEP, assessing their correlation with clinical and cognitive features.
METHODS
The oxytocin and prolactin in plasma was measured in 120 FEP patients and 106 healthy controls, all of whom were subjected to a clinical and neuropsychological assessment. Most patients were under antipsychotics. Statistical analyses aimed to identify factors associated with the FEP and to search for associations between the variables. This study is preliminary and exploratory because the P-values were not corrected for multiple comparisons.
RESULTS
FEP patients had less oxytocin, more prolactin, and a poor premorbid IQ, and they performed worse in sustained attention. Male patients with higher prolactin levels experienced more severe psychotic symptoms and required higher doses of antipsychotics. Low oxytocin was associated with poor sustained attention in women, whereas low oxytocin and high prolactin in men correlated with better performance in sustained attention.
CONCLUSION
Low oxytocin, high prolactin, and poor premorbid IQ and sustained attention are factors associated with an FEP, representing potential therapeutic targets in these patients. These biological factors and cognitive domains might play an important role during a FEP, which could help us to develop new strategies that improve the outcomes of this disorder and that should perhaps be gender specific.
Identifiants
pubmed: 35353882
pii: 6556066
doi: 10.1093/ijnp/pyac023
pmc: PMC9380712
doi:
Substances chimiques
Antipsychotic Agents
0
Oxytocin
50-56-6
Prolactin
9002-62-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
666-677Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of CINP.
Références
Int J Neuropsychopharmacol. 2014 Oct 31;18(2):
pubmed: 25577666
Psychoneuroendocrinology. 2019 Apr;102:24-36
pubmed: 30503781
Dialogues Clin Neurosci. 2015 Dec;17(4):463-76
pubmed: 26869847
Schizophr Res Cogn. 2015 Dec 17;2(4):172-178
pubmed: 29114461
Schizophr Res. 2016 Jul;174(1-3):156-160
pubmed: 27068570
J Psychopharmacol. 2010 Jul;24(7):1011-8
pubmed: 19825908
Psychol Med. 2013 Dec;43(12):2571-82
pubmed: 23590895
Psychol Med. 2016 Jul;46(10):2133-44
pubmed: 27055381
Harv Rev Psychiatry. 2013 Sep-Oct;21(5):219-47
pubmed: 24651556
PLoS One. 2014 Feb 24;9(2):e89428
pubmed: 24586772
J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8
pubmed: 9204677
Am J Psychiatry. 2010 Jun;167(6):686-93
pubmed: 20360319
CNS Drugs. 2016 Mar;30(3):193-208
pubmed: 26895254
Psychosom Med. 2011 Jun;73(5):393-400
pubmed: 21636661
Aust N Z J Psychiatry. 2016 May;50(5):410-72
pubmed: 27106681
Biol Psychiatry. 2008 Jul 1;64(1):4-10
pubmed: 18466880
J Psychiatr Res. 2016 Apr;75:14-21
pubmed: 26783729
Schizophr Bull. 2014 Mar;40(2):376-87
pubmed: 23486748
Neurosci Biobehav Rev. 2017 Sep;80:36-56
pubmed: 28506922
Schizophr Res. 2017 Nov;189:134-141
pubmed: 28223031
Lancet Psychiatry. 2017 Jan;4(1):63-72
pubmed: 27856396
Schizophr Res. 2012 Aug;139(1-3):201-6
pubmed: 22742979
J Endocrinol. 2015 Aug;226(2):T101-22
pubmed: 26101377
Schizophr Res. 2010 Dec;124(1-3):13-21
pubmed: 20947304
Biol Psychiatry. 2016 Feb 1;79(3):222-33
pubmed: 26410353
Aust N Z J Psychiatry. 2018 Jun;52(6):585-595
pubmed: 29232966
Science. 2000 Mar 17;287(5460):2020-2
pubmed: 10720329
Psychopharmacology (Berl). 1981;73(2):184-7
pubmed: 6785813
CNS Drugs. 2014 May;28(5):421-53
pubmed: 24677189
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Eur Arch Psychiatry Clin Neurosci. 2010 Apr;260(3):225-33
pubmed: 19768481
Schizophr Res. 1994 Feb;11(3):273-6
pubmed: 7910756
Arch Gen Psychiatry. 1999 Mar;56(3):241-7
pubmed: 10078501
Psychoneuroendocrinology. 2003 Jan;28 Suppl 1:53-67
pubmed: 12504072
Psychiatry Res. 2018 Jan;259:36-43
pubmed: 29028522
Schizophr Res. 2018 Jul;197:370-377
pubmed: 29275855
Psychiatr Danub. 2019 Jun;31(Suppl 2):148-152
pubmed: 31158115
Schizophr Res. 2008 Jan;98(1-3):247-55
pubmed: 17961988
Schizophr Res. 2013 May;146(1-3):138-43
pubmed: 23465965
Arch Gen Psychiatry. 1976 Jun;33(6):766-71
pubmed: 938196
Can J Psychiatry. 1997 Mar;42(2):139-51
pubmed: 9067063
Expert Opin Investig Drugs. 2000 Apr;9(4):819-28
pubmed: 11060712
Int J Psychiatry Clin Pract. 2016 Sep;20(3):165-9
pubmed: 27334805
Acta Psychiatr Scand. 2020 Oct;142(4):319-325
pubmed: 32740913
Rev Psiquiatr Salud Ment. 2014 Apr-Jun;7(2):61-3
pubmed: 24793240
Psychopharmacology (Berl). 1996 Mar;124(1-2):159-67
pubmed: 8935812
Arch Gen Psychiatry. 1983 Nov;40(11):1228-31
pubmed: 6639293
Arch Womens Ment Health. 2019 Jun;22(3):367-373
pubmed: 30097769
Rev Psiquiatr Salud Ment. 2013 Jan-Mar;6(1):4-16
pubmed: 23206389
J Psychiatr Res. 2019 May;112:38-43
pubmed: 30849617
Transl Psychiatry. 2020 Jun 22;10(1):203
pubmed: 32572020
Biol Psychiatry. 2004 Sep 1;56(5):301-7
pubmed: 15336511
Psychiatry Res. 2016 Jul 30;241:207-20
pubmed: 27183106
J Psychiatr Res. 2015 Jan;60:163-9
pubmed: 25466832
Schizophr Res. 2011 Aug;130(1-3):266-70
pubmed: 21684122
Psychoneuroendocrinology. 1985;10(2):187-91
pubmed: 4034849
Schizophr Res. 2015 May;164(1-3):65-73
pubmed: 25819935
Brain Struct Funct. 2020 Jan;225(1):285-304
pubmed: 31820102
Channels (Austin). 2014;8(3):193-202
pubmed: 24758841
Arch Gen Psychiatry. 2007 Jan;64(1):19-28
pubmed: 17199051
Schizophr Res. 2012 Jan;134(1):16-9
pubmed: 21831600
Eur Arch Psychiatry Clin Neurosci. 2000;250(6):304-10
pubmed: 11153965
Front Psychiatry. 2014 Jan 08;4:182
pubmed: 24409157
Schizophr Res. 2017 Nov;189:111-116
pubmed: 28214176
Front Psychiatry. 2021 Mar 19;12:643112
pubmed: 33815175
Schizophr Bull. 2009 May;35(3):549-62
pubmed: 19325164
Psychiatry Res. 1994 Jul;53(1):31-40
pubmed: 7991730
Physiol Rev. 2018 Jul 1;98(3):1805-1908
pubmed: 29897293
J Psychiatr Res. 2021 Apr;136:428-434
pubmed: 32948308